ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-cell Lymphoma

¹Vanderbilt University Medical Center, Nashville, TN, USA; ³Stanford University, Chicago, IL, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; ³Stanford University, Stanford, CA, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Comprehensive Cancer Center, New York, NY, USA; ⁴Robert H. Lurie Center, New York, NY, USA; ⁴Ro ⁷Levine Cancer Institute, Atrium Health, Charlotte, NC, USA; ⁸Moffitt Cancer Center, Tampa, FL, USA; ⁹Kite, a Gilead Company, Santa Monica, CA, USA; ¹⁰Humanigen Inc., Burlingame, CA, USA; ¹¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA

BACKGROUND


- Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after ≥ 2 lines of systemic therapy and recently, in the United States, for R/R LBCL within 12 months of first-line chemoimmunotherapy¹
- Clinically significant Grade \geq 3 neurologic events (NEs) and cytokine release syndrome (CRS) were reported in the registrational ZUMA-1 and ZUMA-7 studies^{2,3}
- ZUMA-1: NEs, 32% of patients; CRS, 11%
- ZUMA-7: NEs, 21%; CRS, 6%
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) levels after axi-cel infusion were positively associated with Grade \geq 3 NEs in ZUMA-1 and both Grade \geq 3 NEs and CRS in ZUMA-7^{4,5}
- Preclinical evidence indicates that inhibition of the GM-CSF axis with lenzilumab, a humanized anti–GM-CSF IgG1κ monoclonal antibody, may have the potential to suppress some CAR T-cell toxicities without impairing efficacy⁶

OBJECTIVE

• To evaluate the safety and efficacy of axi-cel in combination with lenzilumab in adult patients with R/R LBCL in the Phase 1 ZUMA-19 trial (NCT04314843)

METHODS

Figure 1. ZUMA-19 Study Design



Exploratory Endpoint Lenzilumab pharmacokinetics

Data cutoff date: May 9, 2022.

^aSix hours prior to receiving axi-cel. ^bFlat dose of 2×10^8 cells for patients with body weight >100 kg. CRS, cytokine release syndrome; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; LBCL, large B-cell lymphoma; NE, neurologic event; ORR, objective response rate.

- CRS was graded according to a revised system per Lee et al⁷
- Other adverse events (AEs) including NEs were graded according to National Cancer Institute Common Terminology Criteria for AEs (v4.03)
- CAR T-cell levels in the blood were assessed by qPCR
- Serum lenzilumab concentrations were measured by an enzyme-linked immunosorbent assay
- Soluble analytes/markers were measured in the serum by multiplex assays
- Platforms used included MSD[®], Ella[®], or Luminex[®]

RESULTS

PATIENTS

- prior to receiving axi-cel

Table 1. Patient Demographics and Baseline Characteristics

Characteristi Median age, yea Male, n (%) ECOG PS 1, n (% Age-adjusted IP Disease stage, n Histological DLB DLBCL NOS DLBCL arising Cell of origin, n GCB Other Lines of prior the **Refractory subg** Primary refracto Refractory to ≥ Double/triple h Double Median tumor b (range)^d diameters of all target lesions at baseline. **SAFETY**

Table 2. AE Summary

AE, n (%)	Axi-cel + lenzilumab 600 mg (n=3)	Axi-cel + lenzilumab 1,800 mg (n=3)	Overall (N=6)
Grade ≥3 AEs	3 (100)	3 (100)	6 (100)
Grade ≥3 serious AEs	2 (67)	2 (67)	4 (67)
Grade ≥3 axi-cel–related AEs	2 (67)	2 (67)	4 (67)
Any lenzilumab-related AEs	0	0	0
Any NE ^a Worst Grade 1 Worst Grade 2 Worst Grade 3 Worst Grade 4 Worst Grade 5	3 (100) 2 (67) 0 1 (33) 0 0	2 (67) 1 (33) 1 (33) 0 0 0	5 (83) 3 (50) 1 (17) 1 (17) 0 0
Any CRS ^a Worst Grade 1 Worst Grade 2 Worst Grade 3 Worst Grade 4 Worst Grade 5	2 (67) 0 2 (67) 0 0 0	2 (67) 1 (33) 1 (33) 0 0 0	4 (67) 1 (17) 3 (50) 0 0 0
Worst Grade ≥3 infections ^a	1 (33)	2 (67)	3 (50)
Cytopenia present on or after Day 30 ^{a,b}	1 (33)	1 (33)	2 (33)
Any steroid use	2 (67)	2 (67)	4 (67)
Any tocilizumab use	1 (33)	2 (67)	3 (50)

All causality. °Included neutropenia, thrombocytopenia, or anemia; includes events started after 30 days [•] from axi-cel infusion and those started earlier but still ongoing on or after 30 days from axi-cel infusion. AE, adverse event; axi-cel, axicabtagene ciloleucel; CRS, cytokine release syndrome; NE, neurologic event.

Olalekan O. Oluwole, MBBS, MPH¹, Saad S. Kenderian, MD, MB, ChB², Parveen Shiraz, MD³, Reem Karmali, MD⁴, Ran Reshef, MD, MSc⁵, Philip L. McCarthy, MD⁶, Nilanjan Ghosh, MD, PhD⁷, Aleksandr Lazaryan, MD, PhD⁸, Simone Filosto, PhD⁹, Soumya Poddar, PhD⁹, Daqin Mao, PhD⁹, Andrew Peng, MS⁹, Adrian Kilcoyne, MD, MPH¹⁰, Myrna Nahas, MD⁹, Sattva S. Neelapu, MD¹¹

• In Phase 1 of ZUMA-19, 6 patients received either lenzilumab 600 mg in Cohort 1 (n=3) or lenzilumab 1,800 mg in Cohort 2 (n=3) 6 hours

• Median follow-up was 17.1 months (range, 14.7–22.3 months) • Overall, the median age was 59.5 years (range, 51–80 years) and 50% of patients were refractory to ≥ 2 lines of therapy (**Table 1**)

	Axi-cel + lenzilumab 600 mg (n=3)	Axi-cel + lenzilumab 1,800 mg (n=3)	Overall (N=6)
ars (range)	55 (51–80)	61 (58–77)	59.5 (51–80)
	3 (100)	3 (100)	6 (100)
%)	1 (33)	2 (67)	3 (50)
Pl total score, n (%)ª	2 (67) 1 (33)	2 (67) 1 (33)	4 (67) 2 (33)
n (%)	0 2 (67) 1 (33)	2 (67) 0 1 (33)	2 (33) 2 (33) 2 (33)
BCL type, n (%) from FL	2 (67) 1 (33)	1 (33) 2 (67)	3 (50) 3 (50)
(%)	1 (33) 2 (67)	3 (100) 0	4 (67) 2 (33)
nerapy, n (%)	1 (33) 2 (67) 0	1 (33) 1 (33) 1 (33)	2 (33) 3 (50) 1 (17)
group, n (%) ^b ory 2 lines of therapy	1 (33) 2 (67)	0 1 (33)	1 (17) 3 (50)
it status, n (%) [.]	1 (33)	1 (33)	2 (33)
ourden, mm²	5,502 (893–7,846)	1,495 (902–2,830)	2,162.5 (893–7,846)

^aAge-adjusted IPI was based on second line of therapy. ^bData were missing for 2 patients. ^cNo patients had triple hit status; data were not available for 1 patient in Cohort 1. dMeasured by the product of

Axi-cel, axicabtagene ciloleucel; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; GCB, germinal center B cell; IPI, International Prognostic Index; NOS, not otherwise specified.

• As of the data cutoff (May 9, 2022), no DLTs or Grade \geq 3 CRS events were observed in either cohort (**Table 2**)


- No lenzilumab-related AEs were observed in either cohort

- A single Grade \geq 3 axi-cel-related NE (encephalopathy) was observed in Cohort 1
- No Grade \geq 3 NEs (any causality) were observed in Cohort 2 • Median earliest onset of worst grade NE (within first 30 days) in
- Cohort 1 and 2 was 8 and 9.5 days, respectively
- Median earliest onset of worst grade CRS (within first 30 days) in Cohort 1 and 2 was 3 and 4.5 days, respectively

EFFICACY

• Objective and complete response rates were 83% and 67%, respectively (**Figure 2**)

Figure 2. Objective Response and Survival Status Over Time




- Of the 5 patients with a response (CR, n=4; PR, n=1), 4 had a response within 30 days; none had subsequent disease progression
- The patient with a PR died due to COVID-19-related pneumonia • Four of 6 patients died (67%); no deaths were treatment related
- COVID-19 pneumonia, n=3; refractory disease, n=1

PHARMACOKINETICS

- Peak concentrations of circulating CAR T cells, normalized to baseline tumor burden (sum of products of diameters; SPD), were comparable between Cohorts 1 and 2 (range, 0.001–0.03 cells/µL*mm² in both cohorts) (**Figure 3A**)
- Peak CAR T-cell concentrations occurred between Days 7 and 14 after infusion
- Lenzilumab serum concentrations were dose proportional, with , values of 67.1–89.9 μg/mL in Cohort 1 and 249–299 μg/mL in Cohort 2 (Figure 3B)

Figure 3. Pharmacokinetics of Axi-cel and Lenzilumab




Medians are indicated by labeled horizontal bars, and error bars represent range (minimum, maximum). All comparisons between ZUMA-19 Cohorts 1 and 2 and combined ZUMA-1 Cohorts 1 and 2 are descriptive; no formal statistical analysis was conducted. Axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; SPD, sum of products of diameters

• Lenzilumab was sustained above a target serum concentration of 50 µg/mL through Day 1 in Cohort 1 and through Day 4 in Cohort 2

BIOMARKERS


- More than 50% of patients in ZUMA-1 Cohorts 1 and 2 had detectable levels of GM-CSF⁴
- and chemokines and interferon gamma (IFN_Y), compared with no reduction in interleukin-2 (IL-2)



Peak concentrations were defined as the maximum post-baseline level from baseline to Week 4. Filled solid bars represent medians, and error bars represent range (minimum, maximum). Axi-cel, axicabtagene ciloleucel; CXCL10, CXC motif chemokine ligand 10; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; LLOQ, lower limit of quantitation; MCP-1, monocyte chemoattractant protein-1; TNF, tumor necrosis factor.

• Lenzilumab appeared to dose-dependently (in Cohort 2 compared with Cohort 1) reduce the serum concentration of ferritin, amyloid A (SAA), IL-8, and CXC motif chemokine ligand 10 (CXCL10) (Figure 5)

Figure 5. Serum Levels of Acute Phase and Pro-inflammatory Markers Over Time



CXCL10, CXC motif chemokine ligand 10; IL, interleukin; SAA, serum amyloid A.

REFERENCES

1. YESCARTA[®] (axicabtagene ciloleucel) prescribing information. Kite Pharma, Inc; 2022.

- 2. Locke FL, et al. Lancet Oncol. 2019;20(1):31-42. 3. Locke FL, et al. N Engl J Med. 2022;386(7):640-654.
- 4. Neelapu SS, et al. N Engl J Med. 2017;377(26):2531-2544.
- 5. Filosto S, et al. Presented at AACR 2022; abstract CT004.
- 6. Sterner RM, et al. Blood. 2019;133(7):697–709. 7. Lee DW, et al. *Blood*. 2014;124(2):188–195.

ACKNOWLEDGMENTS

- The patients, families, friends, and caregivers
- The study investigators, coordinators, and health care staff at each study site
- Preclinical research was funded in part by NIH R37CA266344 • Medical writing support was provided by Naomi Atkin, PhD, of Fishawack Health, funded by Kite,
- a Gilead Company

• GM-CSF levels were undetectable, based on an MSD[®] multiplex assay, in all patients at all time points through at least Week 4 in ZUMA-19 (Figure 4)


• Across Cohorts 1 and 2, there were lenzilumab dose-dependent reductions in serum concentrations of pro-inflammatory myeloid-related cytokines

Figure 4. Peak Cytokine and Chemokine Concentrations in Patients Treated With Axi-cel Plus Lenzilumab

• The abundance of circulating intermediate monocytes on Day 14 was lower in Cohort 2 compared with Cohort 1 (Figure 6)

Treated With Axi-cel Plus Lenzilumab Day 14 Leukapheresis Day 7

Figure 6. Circulating Intermediate Monocytes in Patients



Circulating monocytes were evaluated by flow cytometry (CD66b⁻CD3⁻CD19⁻CD56⁻HLADR⁺CD14⁺CD16⁺). Filled solid bars represent medians, and error bars represent range (minimum, maximum). Axi-cel, axicabtagene ciloleucel.

CONCLUSIONS

- No DLTs or new safety signals were observed in patients treated with axi-cel plus lenzilumab
- Addition of lenzilumab to the axi-cel regimen appeared to dose-dependently suppress the GM-CSF axis and reduce markers of systemic inflammation
- Axi-cel in combination with lenzilumab may improve the inflammatory profile relative to single-agent axi-cel
- Inhibition of the GM-CSF axis to mitigate CAR T-cell toxicities may warrant further investigation

DISCLOSURES

Full author disclosures are available through the Quick Response (QR) code Copies of this poster obtained through Quick Response Code are for personal use only and may not be reproduced without permission from the author of this poster.

